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MicroRNAs (miRNAs) encoded by the miR-17-92 cluster and its paralogs are known to act as 
oncogenes. Expression of these miRNAs promotes cell proliferation, suppresses apoptosis of 
cancer cells, and induces tumor angiogenesis. New work reveals essential functions for these 
miRNAs not only in tumor formation but also during normal development of the heart, lungs, and 
immune system.Over the last decade, a fundamental role for small RNA-guided 
posttranscriptional regulation of gene expression has been 
uncovered. In particular, the microRNA (miRNA) family of small 
RNA regulators has attracted attention due to its increasingly 
appreciated importance in development and disease. MicroR-
NAs are 18–24 nucleotide single-stranded RNAs that together 
with a complex of associated proteins known as the RNA-
induced silencing complex (RISC) bind to sites of comple-
mentarity in the 3′ untranslated regions of messenger RNAs. 
Targeted mRNAs are subsequently translated less efficiently 
and undergo accelerated turnover (reviewed in Stefani and 
Slack, 2008). MicroRNAs represent an ancient form of gene 
regulation and are present in all multicellular eukaryotes stud-
ied so far and even some unicellular eukaryotes. An explosion 
of high-throughput sequencing efforts have uncovered over 
500 miRNA genes in the human genome, many of which have 
been conserved throughout the vertebrate radiation. Elucida-
tion of miRNA functions, requiring traditional loss- and gain-of-
function experiments in cells and animals, has lagged behind 
these discovery efforts. But as these types of studies have 
been undertaken, the potent phenotypes induced by miRNA 
perturbations have placed these molecules at the center of 
critical cellular and developmental pathways. A series of recent 
papers in Cell, Nature Immunology, and Cancer Cell establish 
essential roles for the miR-17-92 cluster of miRNAs in devel-
opment of the heart, lungs, and immune system (Koralov et 
al., 2008; Ventura et al., 2008; Xiao et al., 2008) and provide 
mechanistic insights into the role of these miRNAs in tumor 
formation (Petrocca et al., 2008).
Genomic Organization of the miR-17-92 Cluster
In animals, miRNAs are frequently transcribed together as 
polycistronic primary transcripts that are processed into mul-
tiple individual mature miRNAs (Stefani and Slack, 2008). The 
genomic organization of these miRNA clusters is often highly 
conserved, suggesting an important role for coordinated reg-
ulation and function. The miR-17-92 cluster is a prototypical 
example of a polycistronic miRNA gene. In the human genome, 
the miR-17-92 cluster encodes six miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1, and miR-92-1), which are tightly 
grouped within an 800 base-pair region of human chromosome 
13 (Figure 1A). Both the sequences of these mature miRNAs 
and their organization are highly conserved in all vertebrates. 
The human miR-17-92 cluster is located in the third intron of a 
~7 kb primary transcript known as C13orf25 (Ota et al., 2004). 
Despite the extreme conservation of the miRNA sequences, 
the exonic sequences of C13orf25 are not measurably con-
strained between species, suggesting that the sole function of 
this transcript is to produce these miRNAs.
Ancient gene duplications have given rise to two miR-17-92 
cluster paralogs in mammals: the miR-106b-25 cluster (located 
on human chromosome 7) and the miR-106a-363 cluster 
(located on the X chromosome) (Figure 1A). The miR-106b-25 
cluster is located within the 13th intron of the protein-coding 
gene MCM7. Unlike the miR-17-92 and miR-106b-25 clusters, 
which are both abundantly expressed across many tissues 
and cell types, the miR-106a-363 cluster is undetectable or 
expressed at trace levels in all settings that have been exam-
ined (Ventura et al., 2008). Perhaps this miRNA polycistron pro-
vides a very specialized function in a cell type yet to be studied 
or represents a nonfunctional pseudogene.
The miR-17-92 Cluster in Cancer
The miR-17-92 cluster first attracted attention following a 
series of observations linking these miRNAs to cancer patho-
genesis. The human genomic locus encoding these miRNAs, 
13q31.3, undergoes amplification in several types of lym-
phoma and solid tumors. Ota et al. (2004) defined a minimal 
amplicon in this region in B cell lymphoma and demonstrated 
that C13orf25 (the miR-17-92 primary transcript) was within this 
interval. C13orf25 expression levels closely mirror the amplifi-
cation status across numerous lymphoma cell lines and tissue 
samples from lymphoma patients. Building on these observa-
tions, the Hannon and Hammond laboratories provided direct 
experimental evidence that the miR-17-92 cluster has onco-
genic activity (He et al., 2005). Enforced expression of these 
miRNAs in the well-studied Eµ-myc transgenic mouse model of 
B cell lymphoma dramatically accelerated disease onset and Cell 133, April 18, 2008 ©2008 Elsevier Inc. 217
Figure 1. Organization of the miR-17-92 Cluster and Its Paralogs
(A) The genomic organization and primary transcript structures of the human miR-17-92, miR-106a-363, and miR-106b-25 clusters. The miR-106a-363 primary 
transcript has not been characterized. 
(B) Based on their seed sequences—which are the regions considered most important for target selection (nucleotides 2–7; shown in blue)—the miRNAs of 
these clusters can be grouped into four families: the miR-17 family (miR-17, miR-20a/b, miR-106a/b, and miR-93); the miR-18 family (miR-18a/b); the miR-19 
family (miR-19a/b); and the miR-25 family (miR-25, miR-92a, and miR-363). MicroRNAs of the miR-17-92 cluster and its paralogs have been implicated in 
normal development of the heart, lungs, and immune system as well as in tumorigenesis.progression. Importantly, lymphomas with enforced expression 
of these miRNAs lacked the high degree of apoptosis that usu-
ally typifies these tumors in Eµ-myc mice. Simultaneously, we 
reported that transcription of the miR-17-92 cluster is directly 
transactivated by c-Myc (O’Donnell et al., 2005), a transcrip-
tion factor that is frequently hyperactive in cancer cells. This 
finding provided one of the first demonstrations that miRNAs 
are functionally integrated into oncogenic pathways central to 
cancer development.
Several independent lines of evidence have further solidi-
fied the case that the miR-17-92 cluster and its paralogs can 
act as bona fide oncogenes. Expression profiling studies have 
revealed widespread overexpression of these miRNAs in diverse 
tumor subtypes including both hematopoietic malignancies 
and solid tumors such as those derived from breast, colon, 
lung, pancreas, prostate, and stomach (Petrocca et al., 2008; 
Volinia et al., 2006). Functional screens have also highlighted 
the importance of these miRNAs. One unbiased and powerful 
strategy for identifying new cancer genes relies upon the clon-
ing of retroviral integration sites in murine malignancies. Given 
that retroviral insertion can lead to ectopic activation of nearby 
genes, multiple integration events at a given locus in indepen-
dent tumors is often a signature of a neighboring oncogene. 
The locus encoding the miR-17-92 cluster is a common inser-
tion site in multiple types of retrovirally induced murine leuke-
mias (Cui et al., 2007; Wang et al., 2006). Interestingly, retroviral 
insertions have been observed at the miR-106a-363 locus in 218 Cell 133, April 18, 2008 ©2008 Elsevier Inc.murine T cell leukemias (Landais et al., 2007). Although expres-
sion of the miR-106a-363 cluster is normally extremely low, this 
finding demonstrates that when ectopically transcribed, these 
miRNAs are functional and may act in a similar manner to the 
miR-17-92 cluster.
Establishment of an important role for the miR-17-92 cluster 
and its paralogs in the regulatory circuitry that controls cellular 
life and death decisions further illuminates the contributions of 
these miRNAs to tumorigenesis. In particular, these miRNAs 
seem to be tightly linked to the functions of the E2F family of 
transcription factors, which are critical regulators of the cell 
cycle and apoptosis. E2F1, E2F2, and E2F3—activating E2Fs 
that induce expression of genes that drive progression from 
G
1 into S phase—were among the first experimentally verified 
targets of the miR-17-92 cluster (O’Donnell et al., 2005; Syl-
vestre et al., 2007; Woods et al., 2007). Moreover, both E2F1 
and E2F3 can directly activate transcription of these miRNAs, 
establishing a negative feedback loop. This circuitry also 
involves the miR-106b-25 cluster as these miRNAs are similarly 
upregulated by and repress translation of E2F1 (Petrocca et al., 
2008). Given that high levels of E2F proteins, especially E2F1, 
can induce apoptosis, this negative feedback may dampen 
E2F activity following a physiologic proliferative signal, thereby 
promoting cell division rather than cell death.
Targeting of the cyclin-dependent kinase inhibitor CDKN1A 
(p21), a potent negative regulator of the G1-S checkpoint, has 
recently emerged as an additional mechanism through which 
miR-17 and related miRNAs (miR-20a, miR-106b, and miR-93) 
influence cell-cycle progression (Ivanovska et al., 2008; Pet-
rocca et al., 2008). In some cell lines, overexpression or inhibi-
tion of this family of miRNAs is sufficient to promote or delay 
the entry of cells into S phase, respectively (Ivanovska et al., 
2008). Similarly, high expression of these miRNA can impair 
cell-cycle arrest induced by DNA damage. Inhibition of p21 by 
this family of miRNAs contributes significantly to these pheno-
types. Signaling via the growth factor TGFβ is another potent 
inducer of p21 and cell-cycle arrest at the G1-S checkpoint. As 
Petrocca and colleagues (2008) report in a recent issue of Can-
cer Cell, overexpression of miR-106b or miR-93 renders gas-
tric cancer cells insensitive to TGFβ-mediated cell-cycle arrest. 
Conversely, inhibition of these miRNAs increases sensitivity to 
TGFβ. Again, these effects are at least partly attributable to 
regulation of p21 by these miRNAs.
A cluster of papers in Cell and Nature Immunology as well 
as Cancer Cell have also identified the proapoptotic gene 
BCL2L11/BIM as a direct target of multiple members of the 
miR-17-92 cluster and related miRNAs (Koralov et al., 2008; 
Petrocca et al., 2008; Ventura et al., 2008; Xiao et al., 2008). 
Bim is a proapoptotic protein that regulates cell death in a 
variety of settings through its ability to antagonize antiapop-
totic proteins such as Bcl2. Interestingly, haploinsufficiency for 
Bim accelerates lymphomagenesis in Eµ-myc transgenic mice 
(Egle et al., 2004). Downregulation of this protein by the miR-
17-92 cluster therefore may contribute to the ability of these 
miRNAs to exacerbate disease progression in this mouse 
model. The antiapoptotic activity of the miR-17-92 cluster and 
related miRNAs in other settings, including TGFβ-stimulated 
gastric cancer cells, may similarly involve downregulation of 
Bim (Petrocca et al., 2008). An important role for regulation of 
Bim by these miRNAs during normal B cell development has 
also been reported (Koralov et al., 2008; Xiao et al., 2008; dis-
cussed below).
The pro-tumorigenic activity of the miR-17-92 cluster addi-
tionally involves cell-nonautonomous functions including 
induction of angiogenesis in solid tumors. The c-Myc onco-
gene is a potent inducer of tumor angiogenesis, and its activa-
tion results in downregulation of antiangiogenic proteins such 
as thrombospondin-1 (Tsp1) and connective tissue growth fac-
tor (CTGF) (Dews et al., 2006). Using a mouse model of colon 
cancer, Dews et al. demonstrated that the angiogenic activity 
of c-Myc is at least in part due to downstream activation of the 
miR-17-92 cluster. Both Tsp1 and CTGF are negatively regu-
lated by these miRNAs, which are potently induced by c-Myc 
in this model. Robust vascularization of tumors can be induced 
either by expression of c-Myc or the miR-17-92 cluster.
Although the data overwhelmingly support a dominant role 
for the miR-17-92 cluster in promoting tumorigenesis, there is 
some evidence suggesting that loss-of-function of these miR-
NAs might be advantageous for cancer cells in certain set-
tings. Loss-of-heterozygosity at the 13q31.3 locus has been 
observed in multiple tumor types, and a recent genome-wide 
analysis of copy number alterations in cancer revealed that the 
miR-17-92 cluster was deleted in 16.5% of ovarian cancers, 
21.9% of breast cancers, and 20% of melanomas (Zhang et 
al., 2006). Consistent with these observations, introduction of miR-17 into breast cancer cell lines reduced proliferation of the 
cancer cells (Hossain et al., 2006). This effect was due in part 
to inhibition of the amplified in breast cancer 1 (AIB1) gene, 
which encodes a transcriptional coactivator of the estrogen 
receptor and E2F1. Although a tumor suppressor role for the 
miR-17-92 cluster remains to be established experimentally in 
vivo, both pro- and antitumorigenic activities of these miRNAs 
are not mutually exclusive as their functions will be dictated by 
which targets are expressed in a given setting.
The miR-17-92 Cluster in Development
Despite a well-established role for the miR-17-92 cluster in 
tumorigenesis, the physiological functions of these miRNAs 
have remained unclear. Now, new work, published in Cell and 
Nature Immunology, from the Jacks and Rajewsky laborato-
ries has begun to illuminate the roles of these miRNAs in nor-
mal development (Ventura et al., 2008; Koralov et al., 2008; 
Xiao et al., 2008). Ventura and colleagues (2008) documented 
the consequences of deletion of the miR-17-92 cluster as well 
as the paralogous miR-106a-363 and miR-106b-25 clusters in 
mice. Importantly, targeting of the miR-106b-25 cluster was 
performed very carefully so as not to disrupt the function of 
its essential protein-coding host transcript, Mcm7. Under-
scoring the importance of careful design of miRNA knockout 
studies, the placement of a neomycin resistance (Neo) cas-
sette within the intron of Mcm7 where the miRNAs are located 
was found to be incompatible with embryonic development. 
Only removal of Neo by further recombination allowed recov-
ery of knockout animals. Absence of the miR-106a-363 and 
miR-106b-25 clusters, either alone or in combination, did not 
result in any obvious phenotype. In contrast, loss-of-function 
of the miR-17-92 cluster resulted in smaller embryos and 
immediate postnatal death of all animals. This was likely due 
to severely hypoplastic lungs and ventricular septal defects in 
the hearts of mice lacking miR-17-92. Some functional redun-
dancy of the miR-17-92 and miR-106b-25 clusters does exist 
as loss of both clusters results in embryonic death associ-
ated with severe cardiac defects and widespread apoptosis. 
Consistent with its trace expression, additional deletion of the 
miR-106a-363 cluster does not cause any further develop-
mental abnormalities.
The precise roles of the miR-17-92 cluster in heart and lung 
development remain unclear. The observations described 
above are nevertheless consistent with the earlier demon-
stration that these miRNAs are normally highly expressed in 
embryonic lung and decrease as mice reach maturity (Lu et 
al., 2007). Moreover, transgenic expression of these miRNAs 
specifically in lung epithelium results in severe developmental 
defects with enhanced proliferation and inhibition of differen-
tiation of epithelial cells. Additional studies will be necessary to 
elucidate the critical targets underlying these phenotypes.
Because of the documented role for the miR-17-92 cluster 
in B cell lymphomagenesis, B cell development was examined 
in detail in knockout animals. During normal development of 
B cells, both the immunoglobulin heavy (IgH) and light (IgL) 
chain genomic loci undergo somatic gene rearrangements 
(VDJ and VJ recombination, respectively), which contributes to 
the diverse antibody repertoire of the mature immune system. Cell 133, April 18, 2008 ©2008 Elsevier Inc. 219
Only a subset of cells that enter this pathway successfully per-
form these rearrangements, and multiple checkpoints exist to 
ensure that all mature B cells express a functional membrane-
bound antibody, the B cell receptor. Successful assembly of 
the IgH locus in progenitor B (pro-B) cells provides a survival 
signal that allows their progression to the precursor B (pre-B) 
cell stage. Subsequent productive assembly of the IgL loci sig-
nals furthers development to the immature B cell stage. A final 
test prior to maturation of these cells ensures that the suc-
cessfully assembled B cell receptor does not react with endog-
enous antigens.
Hematopoiesis in mid-gestation embryos lacking the miR-
17-92 cluster is characterized by a striking deficiency of pre-B 
cells, but not of earlier B cell progenitors (Ventura et al., 2008), 
and a marked increase in apoptosis of developing B cells in 
these animals. By reconstituting the hematopoietic system 
of adult wild-type mice with fetal liver cells from miR-17-92-
deficient embryos, the authors were able to examine the role 
of these miRNAs in adult hematopoiesis. Consistent with the 
effects observed in embryos, there were almost normal num-
bers of pro-B cells but marked depletion of later stage pre-B 
cells and mature B cells, accompanied by increased apoptosis 
specifically of pro-B cells. Based on these data, the authors 
propose that the miR-17-92 cluster is essential for the sur-
vival signal enabling progression from the pro-B to pre-B cell 
stage. This survival signal likely involves downregulation of the 
proapoptotic gene Bcl2l11/Bim, which was shown by these 
authors and others to be a direct target of multiple members of 
the miR-17-92 cluster.
Notably, mouse hematopoiesis occurring in the absence of 
miR-17-92 leads to an isolated defect in B cell development. 
Other hematopoietic cells such as red blood cells, granulo-
cytes, monocytes, and T cells are largely unaffected by loss of 
these miRNAs. This contrasts with the in vitro differentiation of 
human CD34+ hematopoietic progenitor cells. In this system, 
members of the miR-17-92 cluster are downregulated during 
monocyte differentiation (Fontana et al., 2007). This results in 
upregulation of the transcription factor AML1, a direct target 
of miR-17 and related miRNAs that is essential for monocyte 
differentiation. Accordingly, overexpression of these miRNAs 
delays terminal differentiation of monocytes, whereas their 
inhibition accelerates differentiation. Further investigation will 
be necessary to determine whether differences between these 
observations and those of Ventura et al. reflect distinctions 
between human and mouse monocytopoiesis or indicate that 
in vitro differentiation of hematopoietic progenitor cells does 
not fully recapitulate the normal physiology of this process.
Using a different approach, Koralov et al. (2008) also uncov-
ered a role for the miR-17-92 cluster during B cell development. 
In their study, the Dicer gene, which encodes an enzyme that 
is essential for miRNA biogenesis, was deleted specifically in 
developing B cells. The resulting phenotype was similar to the 
effect of miR-17-92 deletion: accumulation of pro-B cells with 
a marked reduction of pre-B cells and more mature cells of 
this lineage. Notably, Dicer deficiency induced apoptosis of 
pre-B cells rather than of pro-B cells as observed in the miR-
17-92-deficient animals. These distinct effects indicate that the 
phenotype due to Dicer deletion cannot be wholly explained 220 Cell 133, April 18, 2008 ©2008 Elsevier Inc.by loss of miR-17-92. Nevertheless, gene expression analyses 
revealed that the 3′ UTRs of genes upregulated upon Dicer 
deletion in pro-B cells are significantly enriched for heptamer 
motifs that are complementary to the seed sequences of mul-
tiple miRNAs from the miR-17-92 cluster and miR-142-3p. A 
high-scoring gene in these analyses, with multiple miR-17-92 
miRNA-binding sites, was the proapoptotic gene Bim. Cells 
lacking Dicer show increased Bim mRNA expression and Bim 
protein production. Consistent with a critical role for aberrant 
expression of this protein in mice lacking Dicer, B cell develop-
ment can be partially rescued in these animals by homozygous 
deletion of Bim. It is also possible, however, that this rescue 
is due to a general lowering of the apoptotic threshold in cells 
lacking Bim rather than a specific effect related to regulation 
of Bim by the miR-17-92 cluster. Indeed, the authors also dem-
onstrate that overexpression of the antiapoptotic protein Bcl2 
similarly rescues B cell development.
The ability of Bim loss-of-function or Bcl2 gain-of-func-
tion to overcome this block in B cell development allowed 
the impact of Dicer deletion on later steps in this develop-
mental pathway to be examined. Recombination of IgH and 
IgL loci occurred normally in the absence of Dicer, but there 
were some aberrant effects. Specifically, an unusual spec-
trum of gene segments was incorporated during VDJ recom-
bination, suggesting altered chromatin structure at the IgH 
locus. Given that Dicer regulates chromatin structure in fis-
sion yeast, this observation, as well as the previous dem-
onstration that both sense and antisense noncoding RNAs 
are produced from the IgH locus, raises the intriguing pos-
sibility that a Dicer-dependent small RNA-guided chromatin 
regulatory pathway exists in mammalian cells (Chakraborty 
et al., 2007). Alternatively, these effects may be second-
ary to loss of miRNA-mediated regulation of a chromatin 
regulatory protein. Dicer deletion was also associated with 
abnormally sustained transcription of terminal deoxynucle-
otidyl transferase (TdT), the enzyme that adds nontemplated 
nucleotides to the recombining gene segments to increase 
antibody diversity, although the mechanism of this phenom-
enon is unclear.
In a complementary study, this group used a gain-of-func-
tion approach to further investigate the role of the miR-17-92 
cluster in development of the immune system (Xiao et al., 
2008). They engineered mice to modestly overexpress these 
miRNAs specifically in the B and T cell lineages. Importantly, 
expression levels of these miRNAs in transgenic animals 
were comparable to levels observed in human lymphoma 
cell lines. Enforced expression of the miR-17-92 cluster 
resulted in premature death of transgenic animals associ-
ated with lymphoproliferative disease and autoimmunity. 
Both the B and especially the T cell compartments were 
expanded in the peripheral immune system. In vitro, B and T 
cells from transgenic animals exhibited increased prolifera-
tion and survival following activation. Based on these find-
ings, the authors propose that pathological amplification of 
the miR-17-92 cluster, as found in human lymphoma cells, 
leads to expansion of cells harboring this lesion, increas-
ing the likelihood of accruing additional mutations leading 
to malignancy.
These investigators (Xiao et al., 2008) highlight not only the 
potential role of Bim regulation by the miR-17-92 cluster in 
these phenotypes but also the role of Pten, a tumor suppres-
sor and additional validated target of these miRNAs (Lewis 
et al., 2003). Combined haploinsufficiency of Bim and Pten 
partially mimics the phenotype of miR-17-92 overexpression, 
highlighting the importance of these proteins but also indicat-
ing that additional targets must contribute to these effects. 
Regulation of E2F transcription factors by these miRNAs 
might also play an important role in miR-17-92 gain-of-func-
tion phenotypes given that deficiency of these proteins simi-
larly leads to hematopoietic malignancies and autoimmunity 
(Zhu et al., 2001).
Future Directions
The available evidence places the miR-17-92 cluster and its 
paralogs at the nexus of critical pathways that regulate cel-
lular life and death decisions during normal development 
and in malignancy. But clearly many questions remain. Of 
particular importance is the continued elucidation of the full 
network of targets regulated by these miRNAs. Given that 
each miRNA perhaps regulates hundreds of mRNAs, this 
will be a daunting task. Further complicating matters, the 
diverse functions of the miR-17-92 cluster and its paralogs 
in different physiological contexts likely involves different 
subsets of targets. More broadly, an emerging issue relates 
to whether the functions of a given miRNA can be attrib-
uted to strong regulation of a select few dominant targets or, 
alternatively, more subtle regulation of many targets simul-
taneously. It is likely that miRNAs act along a spectrum of 
these possibilities, with simple miRNA:target relationships 
dictating some phenotypes and complex networks of gene 
expression changes underlying others. Elucidating where 
along this spectrum the miR-17-92 cluster operates repre-
sents a major challenge for future investigations.
The organization of the miR-17-92 cluster and its paral-
ogs raises interesting questions regarding their redundancy. 
Clearly, there is functional synergy between the miR-17-92 
and miR-106b-25 clusters, as evidenced by the severity of 
the combined knockout phenotype (Ventura et al., 2008). But 
the severe phenotype associated with miR-17-92 deletion 
suggests that unique functions are attributable to these miR-
NAs. Notably, only the miR-17-92 and miR-106a-363 clusters 
encode miR-18 and miR-19 family members (Figure 1A). Given 
that the miR-106a-363 cluster appears to be rarely expressed, 
absence of miR-18 and miR-19 might contribute to the phe-
notypic consequences of miR-17-92 loss of function. Genetic 
rescue strategies would allow direct testing of this hypothesis. 
Another interesting issue relates to intracluster redundancy. 
Specifically, the miR-17-92 cluster contains multiple miRNAs 
of the miR-17 and miR-19 families (Figure 1B). According to 
prevailing target prediction models, these miRNAs should be 
redundant. Yet this organization is highly conserved, suggest-
ing that each miRNA in the cluster has functional importance. 
Perhaps this arrangement simply allows more expression of 
a given miRNA family from a single transcription unit. Alter-
natively, each miRNA in the cluster could provide distinct 
functions. Indeed, related miRNAs can have different target specificities and may be subject to unique posttranscriptional 
regulation. Again, rescue experiments could be designed to 
address these issues.
Further investigation of the functions of the miR-17-92 cluster 
is important beyond contributing to a more complete molecu-
lar understanding of the pathways regulated by these miR-
NAs. Due to their potent effects on cellular proliferation and 
apoptosis, these miRNAs may be attractive targets for cancer 
therapy. MicroRNAs are readily inhibited using antisense oli-
gonucleotides and efforts are underway in both academia and 
industry to develop efficient methods to deliver these agents. If 
miRNA-based therapeutics indeed become a reality, the miR-
17-92 cluster and related miRNAs will undoubtedly be among 
the first to be targeted.
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